Annexure VI

Pre - Shareholding (without PAN)

Format of Holding of Specified securities

1. Name of Listed Entity: **Suven Pharmaceuticals Limited**
2. Scrip Code/Name of Scrip/Class of Security : 543064/ SUVENPHAR/ EQUITY SHARES
3. Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg.31(1)(b)/Reg.31(1)(c)
   a. if under 31(1)(b) then indicate the report for quarter ending 31/12/2023
   b. if under 31(1)(c) then indicate date of allotment/extinguishment
4. Declaration : The Listed entity is required to submit the following declaration to the extent of submission of information:

The Pre-Scheme shareholding pattern has been computed on the basis of the shareholding pattern of the Transferee Company as on 23 February 2024

	Particulars	**YES***	**NO***
a	Whether the Listed Entity has issued any partly paid up shares		No
b	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
c	Whether the Listed Entity has any shares against which depository receipts are issued?		No
d	Whether the Listed Entity has any shares in locked-in?		No
e	Whether any shares held by promoters are pledge or otherwise encumbered?		No

5 The tabular format for disclosure of holding of specified securities is as follows:

SUVEN PHARMACEUTICALS LIMITED * HYD *

Table I - Summary Statement holding of specified securities

Category	Category of Shareholder	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (VII) = (IV)+(V)+(VI)	Shareholding as a % of total no of shares (As a % of (A+B+C2))	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding converttible securities (Including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form
								No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held	
								Class X	Class Y	Total								
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)		(XIII)		(XIV)
(A)	Promoter & Promoter Group	1	127,539,592	-	-	127,539,592	50.10	127,539,592	-	127,539,592	50.10	-	50.10	-	-	-	-	127,539,592
(B)	Public	68,118	127,025,364	-	-	127,025,364	49.90	127,025,364	-	127,025,364	49.90	-	49.90	-	-	-	-	126,621,269
(C)	Non Promoter-Non Public																	
(C1)	Shares underlying DRs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(C2)	Shares held by Employes Trusts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Total:	**68,119**	**254,564,956**	**-**	**-**	**254,564,956**	**100.00**	**254,564,956**	**-**	**254,564,956**	**100.00**	**-**	**100.00**	**-**	**-**	**-**	**-**	**254,160,861**

Note: The above does not include underlying shares that would need to be issued upon exercise of employee stock options

SUVEN PHARMACEUTICALS LIMITED * HYD *

Table II - Statement showing shareholding pattern of the Promoter and Promoter Group

Category	Category & Name of the Shareholder	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (IV+V+VI)	Shareholding as a % of total no of shares (calculated as per SCRR, 1957 (VIII) As a % of (A+B+C2	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding converttible securities (Including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of diluted share capital) (VII)+(X) As a % of (A+B+C2)	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form
								No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held	
								Class X	Class Y	Total								
	(I)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)		(XIII)		(XIV)
(1)	Indian	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1a)	Individuals/Hindu undivided Family	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1b)	Central Government/State Government(s)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1c)	Financial Institutions/Banks	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1d)	Any Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Sub-Total (A)(1)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2)	Foreign	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2a)	Individuals (Non-Resident Individuals/Foreign Individuals	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2b)	Government	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2c)	Institutions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2d)	Foreign Portfolio Investor	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2e)	Any Other	1	127,539,592	-	-	127,539,592	50.10	127,539,592	-	127,539,592	50.10	-	50.10	-	-	-	-	127,539,592
(2e)	BERHYANDA LIMITED	1	127,539,592	-	-	127,539,592	50.10	127,539,592	-	127,539,592	50.10	-	50.10	-	-	-	-	127,539,592
	Sub-Total (A)(2)	1	127,539,592	-	-	127,539,592	50.10	127,539,592	-	127,539,592	50.10	-	50.10	-	-	-	-	127,539,592
	Total Shareholding of Promoter and Promoter Group (A	**1**	**127,539,592**	**-**	**-**	**127,539,592**	**50.10**	**127,539,592**	**-**	**127,539,592**	**50.10**	**-**	**50.10**	**-**	**-**	**-**	**-**	**127,539,592**

SUJEN PHARMACEUTICALS LIMITED * HYD *

Table III - Statement showing shareholding pattern of the Public shareholder

Category	Category & Name of the Shareholder	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (IV+V+VI)	Shareholding as a % of total no of shares (A+B+C2)	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding converttible securities (Including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of diluted share capital)	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form	Sub-categorization of shares		
								No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held		Shareholding (No. of shares) under		
								Class X	Class Y	Total									Sub category (i)	Sub category (ii)	Sub category (iii)
	(I)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)			(XIII)	(XIV)			
(1)	Institutions (Domestic)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1a)	Mutual Funds	21	34,242,891	-	-	34,242,891	13.45	34,242,891	-	34,242,891	13.45	-	13.45	-	-	-	-	34,206,891	-	-	-
(1a)	DSP REGULAR SAVINGS FUND	1	10,711,850	-	-	10,711,850	4.21	10,711,850	-	10,711,850	4.21	-	4.21	-	-	-	-	10,711,850	-	-	-
(1a)	HSBC MIDCAP FUND	1	3,990,865	-	-	3,990,865	1.57	3,990,865	-	3,990,865	1.57	-	1.57	-	-	-	-	3,990,865	-	-	-
(1a)	UTI-UNIT LINKED INSURANCE PLAN	1	9,636,095	-	-	9,636,095	3.79	9,636,095	-	9,636,095	3.79	-	3.79	-	-	-	-	9,636,095	-	-	-
(1b)	Venture Capital Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1c)	Alternate Investment Funds	9	1,310,288	-	-	1,310,288	0.51	1,310,288	-	1,310,288	0.51	-	0.51	-	-	-	-	1,310,288	-	-	-
(1d)	Banks	2	211	-	-	211	-	211	-	211	-	-	-	-	-	-	-	211	-	-	-
(1e)	Insurance Companies	6	4,974,210	-	-	4,974,210	1.95	4,974,210	-	4,974,210	1.95	-	1.95	-	-	-	-	4,974,210	-	-	-
(1f)	Provident Funds/Pension Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1g)	Asset Reconstruction Companies	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1h)	Soveregin Wealth Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1i)	NBFC Registered with RBI	1	800																		
(1j)	Other Financial Insutitions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1k)	Any Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Sub-Total (B)(1)	**39**	**40,528,400**	**-**	**-**	**40,528,400**	**15.91**	**40,528,400**	**-**	**40,528,400**	**15.91**	**-**	**15.91**	**-**	**-**	**-**	**-**	**40,492,400**	**-**	**-**	**-**
(2)	Institutions (Foreign)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2a)	Foreign Direct Investment	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2b)	Foreign Venture Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2c)	Sovereign Wealth Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2d)	Foreign Portfolio Investors Category I	119	26,766,467	-	-	26,766,467	10.51	26,766,467	-	26,766,467	10.51	-	10.51	-	-	-	-	26,766,467	-	-	-
(2d)	GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQU	1	2,688,678	-	-	2,688,678	1.06	2,688,678	-	2,688,678	1.06	-	1.06	-	-	-	-	2,688,678	-	-	-
(2d)	AMANSA HOLDINGS PRIVATE LIMITED	1	6,060,898	-	-	6,060,898	2.38	6,060,898	-	6,060,898	2.38	-	2.38	-	-	-	-	6,060,898	-	-	-
(2e)	Foreign Portfolio Investors Category II	11	719,908	-	-	719,908	0.28	719,908	-	719,908	0.28	-	0.28	-	-	-	-	719,908	-	-	-
(2f)	Overseas Depositories (holding DRs) (balancing figure)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2g)	Any Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Sub-Total (B)(2)	**130**	**27,486,375**	**-**	**-**	**27,486,375**	**10.79**	**27,486,375**	**-**	**27,486,375**	**10.79**	**-**	**10.79**	**-**	**-**	**-**	**-**	**27,486,375**	**-**	**-**	**-**
(3)	Central Government/State Government(s)/President of I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(3a)	Central Government / President of India	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(3b)	State Government / Governor	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(3c)	Shareholding by Companies or Bodies Corporate where C	1	25,393	-	-	25,393	0.01	25,393	-	25,393	0.01	-	0.01	-	-	-	-	25,393	-	-	-
(4)	Non-Institutions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4a)	Associate companies / Subsidiaries	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4b)	Directors and their relatives (excluding independent dire	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4c)	Key Managerial Personnel	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4d)	Relatives of promoters (other than 'immediate relatives'	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4e)	Trusts where any person belonging to 'Promoter and Pro	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4f)	Investor Education and Protection Fund (IEPF)	1	348,638	-	-	348,638	0.14	348,638	-	348,638	0.14	-	0.14	-	-	-	-	348,638	-	-	-
(4g)	Resident Individuals holding nominal share capital up to	64,002	26,224,817	-	-	26,224,817	10.30	26,224,817	-	26,224,817	10.30	-	10.30	-	-	-	-	25,861,222	-	-	-
(4h)	Resident Individuals holding nominal share capital in exce	2	718,549	-	-	718,549	0.28	718,549	-	718,549	0.28	-	0.28	-	-	-	-	718,549	-	-	-
(4i)	Non Resident Indians (NRIs)	2,193	2,351,833	-	-	2,351,833	0.92	2,351,833	-	2,351,833	0.92	-	0.92	-	-	-	-	2,351,833	-	-	-
(4j)	Foreign Nationals	2	94,400	-	-	94,400	0.04	94,400	-	94,400	0.04	-	0.04	-	-	-	-	94,400	-	-	-
(4k)	Foreign Companies	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4l)	Bodies Corporate	571	28,209,910	-	-	28,209,910	11.08	28,209,910	-	28,209,910	11.08	-	11.08	-	-	-	-	28,205,910	-	-	-
(4l)	JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITE	1	25,192,957	-	-	25,192,957	9.90	25,192,957	-	25,192,957	9.90	-	9.90	-	-	-	-	25,192,957	-	-	-
(4m)	Any Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4m)	CLEARING MEMBERS	4	17,977	-	-	17,977	0.01	17,977	-	17,977	0.01	-	0.01	-	-	-	-	17,977	-	-	-
(4m)	H U F	1,165	976,235	-	-	976,235	0.38	976,235	-	976,235	0.38	-	0.38	-	-	-	-	975,735	-	-	-
(4m)	TRUSTS	8	42,837	-	-	42,837	0.02	42,837	-	42,837	0.02	-	0.02	-	-	-	-	42,837	-	-	-
	Sub-Total (B)(3)	**67,948**	**58,985,196**	**-**	**-**	**58,985,196**	**23.17**	**58,985,196**	**-**	**58,985,196**	**23.17**	**-**	**23.17**	**-**	**-**	**-**	**-**	**58,617,101**	**-**	**-**	**-**
	Total Public Shareholding (B) = (B)(1)+(B)(2)+(B)(3)	**68,118**	**127,025,364**	**-**	**-**	**127,025,364**	**49.88**	**127,025,364**	**-**	**127,025,364**	**49.88**	**-**	**49.88**	**-**	**-**	**-**	**-**	**126,621,269**	**-**	**-**	**-**

SUVEN PHARMACEUTICALS LIMITED * HYD *

Table IV - Statement showing shareholding pattern of the Non Promoter - Non Public Shareholder

Category	Category & Name of the Shareholder	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (IV+V+VI)	Shareholding as a % of total no of shares (A+B+C2)	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding converttible securities (Including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of diluted share capital)	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form
								No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held	
								Class X	Class Y	Total								
	(I)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)			(XIII)	(XIV)
(1)	Custodian/DR Holder	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2)	Employee Benefit Trust (under SEBI(Share based Employ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Total Non-Promoter-Non Public Shareholding (C) = (C)(1	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**

SUVEN PHARMACEUTICALS LIMITED * HYD *

Details of the shareholders acting as persons in Concert including their Shareholding:			
Name of Shareholder	Name of PAC	No of shares	Holding%
Total:		**0**	**0**

SUVEN PHARMACEUTICALS LIMITED * HYD *

Details of Shares which remain unclaimed may be given hear along with details such as number of shareholders,	
No of Shareholders	No of shares

SUVEN PHARMACEUTICALS LIMITED * HYD *

Significant Beneficial Owners (SBOs)

Sno	Details of the significant beneficial owner			Details of the registered owner				Details of holding/ exercise of right of the SBO in the reporting company, whether direct or indirect*:					Date of creation / acquisition of significant beneficial interest
	I			II				III		IV			
Sr No	Name	Nationality	Nationality (Applicable in case of Any other is selected)	Name	Passport No. in case of a foreign national	Nationality	Nationality (Applicable in case of Any other is selected)	Shares	Voting rights	Rights on distributable dividend or any other distribution	Exercise of control	Exercise of significant influence	
1	Susan Gentile	United States of America		Berhyanda Limited		Any other	Cyprus	50.10%			No	No	Friday, September 29, 2023

SUVEN PHARMACEUTICALS LIMITED * HYD *

Table VI - Statement showing foreign ownership limits

	Board approved limits	Limits utilized	Date
As on shareholding date	74.00	61.53	Friday, February 23, 2024
As on the end of previous 1st quarter	74.00	60.93	Friday, December 29, 2023
As on the end of previous 2nd quarter	74.00	10.73	Thursday, September 28, 2023
As on the end of previous 3rd quarter	74.00	12.47	Friday, June 30, 2023
As on the end of previous 4th quarter	74.00	12.46	Friday, March 31, 2023

SUVEN PHARMACEUTICALS LIMITED * HYD *

Post - Shareholding (without PAN)

Format of Holding of Specified securities

1. Name of Listed Entity : **Suven Pharmaceuticals Limited**
2. Scrip Code/Name of Scrip/Class of Security : 543064/ SUVENPHAR/ EQUITY SHARES
3. Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg.31(1)(b)/Reg.31(1)(c)
   a. if under 31(1)(b) then indicate the report for quarter ending 31/12/2023
   b. if under 31(1)(c) then indicate date of allotment/extinguishment
4. Declaration : The Listed entity is required to submit the following declaration to the extent of submission of information:

   The Post-Scheme shareholding pattern has been computed on the basis of the shareholding pattern of the Transferee Company as on 23 February 2024.The post shareholding pattern may change on the basis of shares held on the date of allotment

	Particulars	**YES***	**NO***
a	Whether the Listed Entity has issued any partly paid up shares		No
b	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
c	Whether the Listed Entity has any shares against which depository receipts are issued?		No
d	Whether the Listed Entity has any shares in locked-in?		No
e	Whether any shares held by promoters are pledge or otherwise encumbered?		No

5 The tabular format for disclosure of holding of specified securities is as follows:

SUVEN PHARMACEUTICALS LIMITED * HYD *

Table I - Summary Statement holding of specified securities

Category	Category of Shareholder	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (VII) = (IV)+(V)+(VI)	Shareholding as a % of total no of shares (As a % of (A+B+C2))	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding converttible securities (Including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form
								No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held	
								Class X	Class Y	Total								
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)		(XIII)		(XIV)
(A)	Promoter & Promoter Group [Note 1]	2	254,078,170	-	-	254,078,170	66.66	254,078,170	-	254,078,170	66.66	-	66.66	-	-	-	-	254,078,170
(B)	Public	68,121	127,067,422	-	-	127,067,422	33.34	127,067,422	-	127,067,422	33.34	-	33.34	-	-	-	-	127,067,422
(C)	Non Promoter-Non Public																	
(C1)	Shares underlying DRs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(C2)	Shares held by Employes Trusts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Total:	**68,123**	**381,145,592**	**-**	**-**	**381,145,592**	**100.00**	**381,145,592**	**-**	**381,145,592**	**100.00**	**-**	**100.00**	**-**	**-**	**-**	**-**	**381,145,592**

Note 1: Includes 40 shares held by 6 nominee shareholders of Jusmiral Holdings Limited

Note 2: The above does not include underlying shares that would need to be issued upon exercise of employee stock options

SUVEN PHARMACEUTICALS LIMITED * HYD *

Category	Category & Name of the Shareholder	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (IV+V+VI)	Shareholding as a % of total no of shares (calculated as per SCRR, 1957 (VIII) As a % of (A+B+C2	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding converttible securities (Including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of diluted share capital) (VII)+(X) As a % of (A+B+C2)	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form
								No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held	
								Class X	Class Y	Total								
	(I)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)		(XIII)		(XIV)
(1)	Indian	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1a)	Individuals/Hindu undivided Family	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1b)	Central Government/State Government(s)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1c)	Financial Institutions/Banks	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1d)	Any Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Sub-Total (A)(1)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2)	Foreign	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2a)	Individuals (Non-Resident Individuals/Foreign Individuals	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2b)	Government	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2c)	Institutions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2d)	Foreign Portfolio Investor	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2e)	Any Other	2	254,078,170	-	-	254,078,170	66.66	254,078,170	-	254,078,170	66.66	-	66.66	-	-	-	-	254,078,170
(2e)	BERHYANDA LIMITED	1	127,539,592	-	-	127,539,592	33.46	127,539,592	-	127,539,592	33.46	-	33.46	-	-	-	-	127,539,592
(2e)	Jusmiral Holdings Limited (Note 1)	1	126,538,578			126,538,578	33.20	126,538,578		126,538,578	33.20		33.20					126,538,578
	Sub-Total (A)(2)	2	254,078,170	-	-	254,078,170	66.66	254,078,170	-	254,078,170	66.66	-	66.66	-	-	-	-	254,078,170
	Total Shareholding of Promoter and Promoter Group (A	**2**	**254,078,170**	**-**	**-**	**254,078,170**	**66.66**	**254,078,170**	**-**	**254,078,170**	**66.66**	**-**	**66.66**	**-**	**-**	**-**	**-**	**254,078,170**

Note 1: Includes 40 shares held by 6 nominee shareholders of Jusmiral Holdings Limited

SUVEN PHARMACEUTICALS LIMITED * HYD *

Table III - Statement showing shareholding pattern of the Public shareholder

Category	Category & Name of the Shareholder	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (IV+V+VI)	Shareholding as a % of total no of shares (A+B+C2)	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding converttible securities (Including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of diluted share capital)	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form	Sub-categorization of shares		
								No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held		Shareholding (No. of shares) under		
								Class X	Class Y	Total									Sub category (i)	Sub category (ii)	Sub category (iii)
	(I)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)			(XIII)	(XIV)			
(1)	Institutions (Domestic)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1a)	Mutual Funds	21	34,242,891	-	-	34,242,891	8.98	34,242,891	-	34,242,891	8.98	-	8.98	-	-	-	-	34,242,891	-	-	-
(1a)	DSP REGULAR SAVINGS FUND	1	10,711,850	-	-	10,711,850	2.81	10,711,850	-	10,711,850	2.81	-	2.81	-	-	-	-	10,711,850	-	-	-
(1a)	HSBC MIDCAP FUND	1	3,990,865	-	-	3,990,865	1.05	3,990,865	-	3,990,865	1.05	-	1.05	-	-	-	-	3,990,865	-	-	-
(1a)	UTI-UNIT LINKED INSURANCE PLAN	1	9,636,095	-	-	9,636,095	2.53	9,636,095	-	9,636,095	2.53	-	2.53	-	-	-	-	9,636,095	-	-	-
(1b)	Venture Capital Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1c)	Alternate Investment Funds	9	1,310,288	-	-	1,310,288	0.34	1,310,288	-	1,310,288	0.34	-	0.34	-	-	-	-	1,310,288	-	-	-
(1d)	Banks	2	211	-	-	211	0.00	211	-	211	0.00	-	0.00	-	-	-	-	211	-	-	-
(1e)	Insurance Companies	6	4,974,210	-	-	4,974,210	1.31	4,974,210	-	4,974,210	1.31	-	1.31	-	-	-	-	4,974,210	-	-	-
(1f)	Provident Funds/Pension Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1g)	Asset Reconstruction Companies	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1h)	Soveregin Wealth Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1i)	NBFC Registered with RBI	1	800	-	-	800	0.00	800	-	800	0.00	-	0.00	-	-	-	-	800	-		
(1j)	Other Financial Insutitions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(1k)	Any Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Sub-Total (B)(1)	**39**	**40,528,400**	**-**	**-**	**40,528,400**	**10.63**	**40,528,400**	**-**	**40,528,400**	**10.63**	**-**	**10.63**	**-**	**-**	**-**	**-**	**40,492,400**	**-**	**-**	**-**
(2)	Institutions (Foreign)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2a)	Foreign Direct Investment	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2b)	Foreign Venture Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2c)	Sovereign Wealth Funds	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2d)	Foreign Portfolio Investors Category I	119	26,766,467	-	-	26,766,467	7.02	26,766,467	-	26,766,467	7.02	-	7.02	-	-	-	-	26,766,467	-	-	-
(2d)	AMANSA HOLDINGS PRIVATE LIMITED	1	6,060,898	-	-	6,060,898	1.59	6,060,898	-	6,060,898	1.59	-	1.59	-	-	-	-	6,060,898	-	-	-
(2e)	Foreign Portfolio Investors Category II	11	719,908	-	-	719,908	0.19	719,908	-	719,908	0.19	-	0.19	-	-	-	-	719,908	-	-	-
(2f)	Overseas Depositories (holding DRs) (balancing figure)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2g)	Any Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Sub-Total (B)(2)	**130**	**27,486,375**	**-**	**-**	**27,486,375**	**7.21**	**27,486,375**	**-**	**27,486,375**	**7.21**	**-**	**7.21**	**-**	**-**	**-**	**-**	**27,486,375**	**-**	**-**	**-**
(3)	Central Government/State Government(s)/President of I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(3a)	Central Government / President of India	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(3b)	State Government / Governor	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(3c)	Shareholding by Companies or Bodies Corporate where C	1	25,393	-	-	25,393	0.01	25,393	-	25,393	0.01	-	0.01	-	-	-	-	25,393	-	-	-
(4)	Non-Institutions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4a)	Associate companies / Subsidiaries	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4b)	Directors and their relatives (excluding independent dire	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4c)	Key Managerial Personnel	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4d)	Relatives of promoters (other than 'immediate relatives'	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4e)	Trusts where any person belonging to 'Promoter and Pro	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4f)	Investor Education and Protection Fund (IEPF)	1	348,638	-	-	348,638	0.09	348,638	-	348,638	0.09	-	0.09	-	-	-	-	348,638	-	-	-
(4g)	Resident Individuals holding nominal share capital up to	64,004	26,231,974	-	-	26,231,974	6.88	26,231,974	-	26,231,974	6.88	-	6.88	-	-	-	-	25,868,379	-	-	-
(4h)	Resident Individuals holding nominal share capital in exce	2	718,549	-	-	718,549	0.19	718,549	-	718,549	0.19	-	0.19	-	-	-	-	718,549	-	-	-
(4i)	Non Resident Indians (NRIs)	2,193	2,351,833	-	-	2,351,833	0.62	2,351,833	-	2,351,833	0.62	-	0.62	-	-	-	-	2,351,833	-	-	-
(4j)	Foreign Nationals	2	94,400	-	-	94,400	0.02	94,400	-	94,400	0.02	-	0.02	-	-	-	-	94,400	-	-	-
(4k)	Foreign Companies	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4l)	Bodies Corporate	572	28,244,811	-	-	28,244,811	7.41	28,244,811	-	28,244,811	7.41	-	7.41	-	-	-	-	28,240,812	-	-	-
(4l)	JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITE	1	25,192,957	-	-	25,192,957	6.61	25,192,957	-	25,192,957	6.61	-	6.61	-	-	-	-	25,192,957	-	-	-
(4m)	Any Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(4m)	CLEARING MEMBERS	4	17,977	-	-	17,977	0.00	17,977	-	17,977	0.00	-	0.00	-	-	-	-	17,977	-	-	-
(4m)	H U F	1,165	976,235	-	-	976,235	0.26	976,235	-	976,235	0.26	-	0.26	-	-	-	-	975,735	-	-	-
(4m)	TRUSTS	8	42,837	-	-	42,837	0.01	42,837	-	42,837	0.01	-	0.01	-	-	-	-	42,837	-	-	-
	Sub-Total (B)(3)	**67,952**	**59,052,647**	**-**	**-**	**59,052,647**	**15.49**	**59,052,647**	**-**	**59,052,647**	**15.49**	**-**	**15.49**	**-**	**-**	**-**	**-**	**58,684,553**	**-**	**-**	**-**
	Total Public Shareholding (B) = (B)(1)+(B)(2)+(B)(3)	**68,121**	**127,067,422**	**-**	**-**	**127,067,422**	**33.34**	**127,067,422**	**-**	**127,067,422**	**33.34**	**-**	**33.34**	**-**	**-**	**-**	**-**	**126,663,328**	**-**	**-**	**-**

SUVEN PHARMACEUTICALS LIMITED * HYD *

Table IV - Statement showing shareholding pattern of the Non Promoter - Non Public Shareholder

Category	Category & Name of the Shareholder	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (IV+V+VI)	Shareholding as a % of total no of shares (A+B+C2)	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding converttible securities (Including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of diluted share capital)	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form
								No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held	
								Class X	Class Y	Total								
	(I)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)		(XIII)		(XIV)
(1)	Custodian/DR Holder	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(2)	Employee Benefit Trust (under SEBI(Share based Employ	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Total Non-Promoter-Non Public Shareholding (C) = (C)(1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

SUJANA PHARMACEUTICALS LIMITED * HYD *

Details of the shareholders acting as persons in Concert including their Shareholding:			
Name of Shareholder	Name of PAC	No of shares	Holding%
Total:		**0**	**0**

SUVEN PHARMACEUTICALS LIMITED * HYD *

Details of Shares which remain unclaimed may be given hear along with details such as number of shareholders,	
No of Shareholders	No of shares

SUVEN PHARMACEUTICALS LIMITED * HYD *

Significant Beneficial Owners (SBOs)

Sno	Details of the significant beneficial owner			Details of the registered owner				Details of holding/ exercise of right of the SBO in the reporting company, whether direct or indirect*:					
	I			II				III		IV			
Sr No	Name	Nationality	Nationality (Applicable in case of Any other is selected)	Name	Passport No. in case of a foreign national	Nationality	Nationality (Applicable in case of Any other is selected)	Shares	Voting rights	Rights on distributable dividend or any other distribution	Exercise of control	Exercise of significant influence	Date of creation / acquisition of significant beneficial interest
1	Susan Gentile	United States of America		Berhyanda Limited		Any other	Cyprus	33.46%			No	No	Friday, September 29, 2023
2	Susan Gentile	United States of America		Jusmiral Holdings Limited		Any other	Cyprus	33.20%			No	No	Date of allotment of shares by the Transferee Company in accordance with the Scheme

SUVEN PHARMACEUTICALS LIMITED * HYD *

Table VI - Statement showing foreign ownership limits

	Board approved limits	Limits utilized	Date
As on shareholding date	74.00	74.49	Date of allotment of shares by the Transferee Company in accordance with the Scheme
As on the end of previous 1st quarter	NA	NA	NA
As on the end of previous 2nd quarter	NA	NA	NA
As on the end of previous 3rd quarter	NA	NA	NA
As on the end of previous 4th quarter	NA	NA	NA

Note: Please note that the foreign ownership limits utilised have been provided assuming that the data available upon the Scheme becoming effective in due course will be the same as it is on 23 February 2024 . Further, as disclosed in the Scheme, the Scheme is conditional and subject to (where applicable), receipt of approval from the Department of Pharmaceuticals in relation to the acquisition of New Equity Shares (as defined in the Scheme) by the shareholders of the Transferor Company, in the Transferee Company pursuant to the Scheme, if such approval is required pursuant to applicable laws, in the form and manner acceptable to the Amalgamating Companies (as defined in the Scheme).

SUVEN PHARMACEUTICALS LIMITED * HYD *

cohance lifesciences

Pre - Shareholding Without PAN

Format of Holding of Specified securities

1. Name of Listed Entity : Cohance Lifesciences Limited
2. Scrip Code/Name of Scrip/Class of Security : EQUITY SHARES
3. Share Holding Pattern Filed under: Reg. 31(1)(a)/Reg.31(1)(b)/Reg.31(1)(c)
   a. if under 31(1)(b) then indicate the report for quarter ending 31/12/2023
   b. if under 31(1)(c) then indicate date of allotment/extinguishment
4. Declaration : The Listed entity is required to submit the following declaration to the extent of submission of information:

	Particulars	YES*	NO*
a	Whether the Listed Entity has issued any partly paid up shares		No
b	Whether the Listed Entity has issued any Convertible Securities or Warrants?		No
c	Whether the Listed Entity has any shares against which depository receipts are issued?		No
d	Whether the Listed Entity has any shares in locked-in?		No
e	Whether any shares held by promoters are pledge or otherwise encumbered?		No

*if the Listed Entity selectes the option 'NO' for the questions above, the columns for the partly paid up shares, Outstanding Convertible Securities/Warrants, depository receipts, locked-in shares, No of shares pledged or otherwise encumbered by promoters, as applicable, shall not be displayed at the time of dissemination on the Stock Exchange website. Also wherever there is 'No' declared by Listed entity in above table the values will be considered as 'Zero' by default on submission of the format of holding of specified securities.

5 The tabular format for disclosure of holding of specified securities is as follows:

For Cohance Lifesciences Limited

Company Secretary

Cohance Lifesciences Limited
Regd. Office: # 215 Atrium, "C" Wing,
8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC,
Mumbai, Maharashtra - 400093.
CIN: U24100MH2020PLC402958
T 022 65139999
E reachus@cohance.com
W www.cohance.com

Corporate Office :
Unit No - 202, 2nd Floor, B Wing,
Galaxy Towers, Plot No-1,
Hyderabad Knowledge City,
TSIIC, Raidurg, Panmaktha,
Serilingampally Mandal,
Rangareddi Dist., Hyderabad-500 081.
Telangana, India.
T +91 40 44758595

Pre Shareholding

Table I - Summary Statement holding of specified securities

Category	Category of Shareholder	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (VII) = (IV)+(V)+(VI)	Shareholding as a % of total no of shares (As a % of (A+B+C2)) 1=	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding convertible securities (Including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of diluted share capital)	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form
								No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held	
								Class X	Class Y	Total								
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)		(XIII)		(XIV)
(A)	Promoter & Promoter Group@	1	3393534593	0	0	3393534593	99.97	3393534593	0	3393534593	99.97	0	99.97	0	0.00	0	0.00	3393534588 Refer note below
(B)	Public	3	1127926	0	0	1127926	0.03	1127926	0	1127926	0.03	0	0.03	0	0.00	0	0	1127926 Refer note below
(C)	Non Promoter-Non Public																	
(C1)	Shares underlying DRs	0	0	0	0	0	0	0	0	0	0.00	0	0	0	0.00	0	0	0
(C2)	Shares held by Employes Trusts	0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0	0
	Total:	4	3394662519	0	0	3394662519	100.00	3394662519	0	3394662519	100.00	0	100.00	0	0.00	0	0.00	3394662514 Refer note below

Note

@Additionally, there are six nominee shareholders holding 1069 shares on behalf of the Promoter

@32488235920 equity shares issued by the Board on 01.02.2024 are in the process of being issued in dematerialized form

For Cohance Lifesciences Limited

Company Secretary

cohance lifesciences

Table II - Statement showing shareholding pattern of the Promoter and Promoter Group

Category	Category & Name of the Shareholder	PAN	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (IV+V+VI)	Shareholding as a % of total no of shares (calculated as per SCRR, 1957 (VIII) As a % of (A+B+C2	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding converttible securities (Including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of diluted share capital) (VII)+(X) As a % of (A+B+C2)	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form
									No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held	
									Class X	Class Y	Total								
	(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)		(XIII)		(XIV)
(1)	Indian		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1a)	Individuals/Hindu undivided Family		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0.00	0
(1b)	Central Government/State Government(s)		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0.00	0
(1c)	Financial Institutions/Banks		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0.00	0
(1d)	Any Other		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0.00	0
	Sub-Total (A)(1)		**0**	**0**	**0**	**0**	**0**	**0.00**	**0**	**0**	**0**	**0.00**	**0**	**0.00**	**0**	**0.00**	**0**	**0.00**	**0**
(2)	Foreign		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(2a)	Individuals (Non-Resident Individuals/Foreign Individuals		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0.00	0
(2b)	Government		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0.00	0
(2c)	Institutions		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0.00	0
(2d)	Foreign Portfolio Investor		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(2e)	Any Other		1	3393534593	0	0	3393534593	99.97	3393534593	0	3393534593	99.97	0	99.97	0	0.00	0	0.00	3393534588 Refer note below
(2e)	JUSMIRAL HOLDINGS LIMITED		1	3393534593	0	0	3393534593	99.97	3393534593	0	3393534593	99.97	0	99.97	0	0.00	0	0.00	3393534588 Refer note below
	Sub-Total (A)(2)		**1**	**3393534593**	**0**	**0**	**3393534593**	**99.97**	**3393534593**	**0**	**3393534593**	**99.97**	**0**	**99.97**	**0**	**0**	**0**	**0**	3393534588 Refer note below
	Total Shareholding of Promoter and Promoter Group (A)=(A)(1)+(A)(2)		**1**	**3393534593**	**0**	**0**	**3393534593**	**99.97**	**3393534593**	**0**	**3393534593**	**99.97**	**0**	**99.97**	**0**	**0.00**	**0**	**0.00**	3393534588 Refer note below

Note

@Additionally, there are six nominee shareholders holding 1069 shares on behalf of the Jusmiral Holdings Limited

@3393534588 equity shares issued by the Board on 01.02.2024 are in the process of being issued in dematerialized form

For Cohance Lifesciences Limited

Company Secretary

cohance lifesciences

Table III - Statement showing shareholding pattern of the Public shareholder

Category	Category & Name of the Shareholder	PAN	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (IV+V+VI)	Shareholding as a % of total no of shares (A+B+C2)	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding converttible securities (including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of diluted share capital)	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form	Sub-categorization of shares		
									No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held		Shareholding (No. of shares) under		
									Class X	Class Y	Total									Sub category (i)	Sub category (ii)	Sub category (iii)
	(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)		(XIII)		(XIV)			
(1)	Institutions (Domestic)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1a)	Mutual Funds		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1b)	Venture Capital Funds		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1c)	Alternate Investment Funds		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1d)	Banks		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1e)	Insurance Companies		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1f)	Provident Funds/Pension Funds		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1g)	Asset Reconstruction Companies		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1h)	Sovereign Wealth Funds		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1i)	NBFC Registered with RBI		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1j)	Other Financial Insutitions		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(1k)	Any Other		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sub-Total (B)(1)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(2)	Institutions (Foreign)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(2a)	Foreign Direct Investment		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(2b)	Foreign Venture Capital		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(2c)	Sovereign Wealth Funds		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(2d)	Foreign Portfolio Investors Category I		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(2e)	Foreign Portfolio Investors Category II		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(2f)	Overseas Depositories (holding DRs) (balancing figure)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(2g)	Any Other		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sub-Total (B)(2)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(3)	Central Government/State Government(s)/President of I		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0	0	0	0	0
(3a)	Central Government / President of India		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0	0	0	0	0
(3b)	State Government / Governor		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0	0	0	0	0
(3c)	Shareholding by Companies or Bodies Corporate where I		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0	0	0	0	0
(4)	Non-Institutions		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4a)	Associate companies / Subsidiaries		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4b)	Directors and their relatives (excluding independent dire		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4c)	Key Managerial Personnel		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4d)	Relatives of promoters (other than 'immediate relatives'		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4e)	Trusts where any person belonging to 'Promoter and Pro		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4f)	Investor Education and Protection Fund (IEPF)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4g)	Resident Individuals holding nominal share capital up to		1	156	0	0	156	0	156	0	156	0	0	0	0	0	0	0	156 Refer note below	0	0	0
(4h)	Resident Individuals holding nominal share capital in exc		1	191770	0	0	191770	0.01	191770	0	191770	0.01	0	0.01	0	0	0	0	191770 Refer note below	0	0	0
(4i)	Non Resident Indians (NRIs)		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4j)	Foreign Nationals		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4k)	Foreign Companies		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4l)	Bodies Corporate		1	936000	0	0	936000	0.03	936000	0	936000	0.03	0	0.03	0	0	0	0	936000 Refer note below	0	0	0
(4m)	Any Other		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4m)	CLEARING MEMBERS		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4m)	H U F		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
(4m)	TRUSTS		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Sub-Total (B)(3)		**3**	**1127926**	**0**	**0**	**1127926**	**0.03**	**1127926**	**0**	**1127926**	**0.03**	**0**	**0.03**	**0**	**0**	**0**	**0**	**1127926 Refer note below**	**0**	**0**	**0**
	Total Public Shareholding (B) = (B)(1)+(B)(2)+(B)(3)		**3**	**1127926**	**0**	**0**	**1127926**	**0.03**	**1127926**	**0**	**1127926**	**0.03**	**0**	**0.03**	**0**	**0**	**0**	**0**	**1127926 Refer note below**	**0**	**0**	**0**

Note
1127926 equity shares issued by the Board on 01.02.2024 are in the process of being issued in dematerialized form

For Cohance Lifesciences Limited

Company Secretary

cohance lifesciences

Table IV - Statement showing shareholding pattern of the Non Promoter - Non Public Shareholder

Category	Category & Name of the Shareholder	PAN	No of Shareholders	No of fully paid up equity shares held	No of Partly paid-up equity shares held	No of Shares Underlying Depository Receipts	Total No of Shares Held (IV+V+VI)	Shareholding as a % of total no of shares (A+B+C2)	Number of Voting Rights held in each class of securities				No of Shares Underlying Outstanding convertible securities (including Warrants)	Shareholding as a % assuming full conversion of convertible Securities (as a percentage of diluted share capital)	Number of Locked in Shares		Number of Shares pledged or otherwise encumbered		Number of equity shares held in dematerialized form
									No of Voting Rights			Total as a % of (A+B+C)			No.	As a % of total Shares held	No.	As a % of total Shares held	
									Class X	Class Y	Total								
	(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)				(X)	(XI)	(XII)		(XIII)		(XIV)
(1)	Custodian/DR Holder		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0	0
(2)	Employee Benefit Trust (under SEBI(Share based Employ		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0	0
	Total Non-Promoter-Non Public Shareholding (C) = (C)(1)+(C)(2)		0	0	0	0	0	0.00	0	0	0	0.00	0	0.00	0	0.00	0	0	0

For Cohance Lifesciences Limited

Company Secretary

cohance lifesciences

cohance lifesciences

Details of the shareholders acting as persons in Concert including their Shareholding:			
Name of Shareholder	Name of PAC	No of shares	Holding%
Total:		0	0

For Cohance Lifesciences Limited

Company Secretary

Details of Shares which remain unclaimed may be given hear along with details such as number of shareholders,	
No of Shareholders	No of shares

For Cohance Lifesciences Limited

Company Secretary

cohance lifesciences

Pre Shareho ding

Significant Beneficial Owners (SBOs)																	
Sno	Details of the significant beneficial owner					Details of the registered owner					Details of holding/ exercise of right of the SBO in the reporting company, whether direct or indirect*:					Date of creation / acquisition of significant beneficial interest
	I					II					III		IV			
Sr No	Name	PAN	Passport No. in case of a foreign national	Nationality	Nationality (Applicable in case of Any other is selected)	Name	PAN	Passport No. in case of a foreign national	Nationality	Nationality (Applicable in case of Any other is selected)	Shares	Voting rights	Rights on distributable dividend or any other distribution	Exercise of control	Exercise of significant influence	
1	Susan Gentile		XXXXXXXX	United States of America		Jusmiral Holdings Limited			Any other	Cyprus	99.97%			No	No	20 July 2020

For Cohance Lifesciences Limited

Company Secretary

For Cohance Lifesciences

Company

For Cohance Lifesciences

cohance lifesciences

cohance lifesciences

Table VI - Statement showing foreign ownership limits			
	Board approved limits	Limits utilized	Date
As on shareholding date	100.00	99.97	23 February 2024
As on the end of previous 1st quarter	100.00	100.00	31 December 2023
As on the end of previous 2nd quarter	100.00	100.00	30 September 2023
As on the end of previous 3rd quarter	100.00	100.00	30 June 2023
As on the end of previous 4th quarter	100.00	100.00	31 March 2023

For Cohance Lifesciences Limited

Company Secretary